TrialJournal of clinical pharmacology2025

Characterizing Cellular Expansion of Idecabtagene Vicleucel and Association with Clinical Efficacy and Safety in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma.

Fan Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.